Search Results

There are 96423 results for: content related to: Identification of Novel Mutations Confirms PDE4D as a Major Gene Causing Acrodysostosis

  1. Identification of Novel Mutations Confirms PDE4D as a Major Gene Causing Acrodysostosis

    Human Mutation

    Volume 34, Issue 1, January 2013, Pages: 97–102, Danielle C. Lynch, David A. Dyment, Lijia Huang, Sarah M. Nikkel, Didier Lacombe, Philippe M. Campeau, Brendan Lee, Carlos A. Bacino, Jacques L. Michaud, Francois P. Bernier, FORGE Canada Consortium, Jillian S. Parboosingh and A. Micheil Innes

    Version of Record online : 9 NOV 2012, DOI: 10.1002/humu.22222

    Corrected by:

    Erratum: Identification of Novel Mutations Confirms PDE4D as a Major Gene Causing Acrodysostosis

    Vol. 34, Issue 4, 667, Version of Record online: 11 FEB 2013

  2. Differential distribution of PDE4D splice variant mRNAs in rat brain suggests association with specific pathways and presynaptical localization

    Synapse

    Volume 45, Issue 4, 15 September 2002, Pages: 259–269, Xavier Miró, Silvia Pérez-Torres, Pere Puigdomènech, José M. Palacios and Guadalupe Mengod

    Version of Record online : 9 JUL 2002, DOI: 10.1002/syn.10100

  3. You have free access to this content
    A new model of Pde4d deficiency: genetic knock-down of PDE4D enzyme in rats produces an antidepressant phenotype without spatial cognitive effects

    Genes, Brain and Behavior

    Volume 11, Issue 5, July 2012, Pages: 614–622, T. L. Schaefer, A. A. Braun, R. M. Amos-Kroohs, M. T. Williams, E. Ostertag and C. V. Vorhees

    Version of Record online : 8 MAY 2012, DOI: 10.1111/j.1601-183X.2012.00796.x

  4. You have free access to this content
    Identification of cyclic AMP-phosphodiesterase variants from the PDE4D gene expressed in human peripheral mononuclear cells

    FEBS Letters

    Volume 384, Issue 1, April 08, 1996, Pages: 97–102, Georges Némoz, RuoBo Zhang, Claudio Sette and Marco Conti

    Version of Record online : 30 NOV 1999, DOI: 10.1016/0014-5793(96)00300-6

  5. You have free access to this content
    Cyclic Nucleotide Phosphodiesterases: important signaling modulators and therapeutic targets

    Oral Diseases

    Volume 21, Issue 1, January 2015, Pages: e25–e50, F Ahmad, T Murata, K Shimizu, E Degerman, D Maurice and V Manganiello

    Version of Record online : 12 SEP 2014, DOI: 10.1111/odi.12275

  6. You have free access to this content
    Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease

    British Journal of Pharmacology

    Volume 157, Issue 6, July 2009, Pages: 892–906, Katharine H Banner and Neil J Press

    Version of Record online : 5 JUN 2009, DOI: 10.1111/j.1476-5381.2009.00170.x

  7. Phosphodiesterase Inhibitors as a Novel Therapeutic Approach for Schizophrenia

    Targets and Emerging Therapies for Schizophrenia

    Judith A. Siuciak, William J. Pitts, Pages: 85–113, 2012

    Published Online : 24 JUN 2012, DOI: 10.1002/9781118309421.ch4

  8. You have full text access to this OnlineOpen article
    The activity of cAMP-phosphodiesterase 4D7 (PDE4D7) is regulated by protein kinase A-dependent phosphorylation within its unique N-terminus

    FEBS Letters

    Volume 589, Issue 6, March 12, 2015, Pages: 750–755, Ashleigh M. Byrne, Christina Elliott, Ralf Hoffmann and George S. Baillie

    Version of Record online : 11 FEB 2015, DOI: 10.1016/j.febslet.2015.02.004

  9. Inhibition of Cyclic Nucleotide Phosphodiesterases to Regulate Memory

    Cyclic-Nucleotide Phosphodiesterases In The Central Nervous System: From Biology to Drug Discovery

    Han-Ting Zhang, Ying Xu, James O'Donnell, Pages: 171–210, 2014

    Published Online : 7 MAR 2014, DOI: 10.1002/9781118836507.ch07

  10. You have free access to this content
    The unique N-terminal domain of the cAMP phosphodiesterase PDE4D4 allows for interaction with specific SH3 domains

    FEBS Letters

    Volume 460, Issue 1, October 22, 1999, Pages: 173–177, Matthew B. Beard, Jonathan C. O'Connell, Graeme B. Bolger and Miles D. Houslay

    Version of Record online : 5 FEB 2002, DOI: 10.1016/S0014-5793(99)01335-6

  11. You have full text access to this OnlineOpen article
    Sub-picomolar relaxin signalling by a pre-assembled RXFP1, AKAP79, AC2, β-arrestin 2, PDE4D3 complex

    The EMBO Journal

    Volume 29, Issue 16, August 18, 2010, Pages: 2772–2787, Michelle L Halls and Dermot M F Cooper

    Version of Record online : 27 JUL 2010, DOI: 10.1038/emboj.2010.168

  12. Temporal and spatial regulation of cAMP signaling in disease: role of cyclic nucleotide phosphodiesterases

    Fundamental & Clinical Pharmacology

    Volume 28, Issue 6, December 2014, Pages: 593–607, Carolina Otero, Juan P. Peñaloza, Paula I. Rodas, Ricardo Fernández-Ramires, Luis Velasquez and Juan E. Jung

    Version of Record online : 12 MAY 2014, DOI: 10.1111/fcp.12080

  13. Proinflammatory cytokine regulation of cyclic AMP-phosphodiesterase 4 signaling in microglia in vitro and following CNS injury

    Glia

    Volume 60, Issue 12, December 2012, Pages: 1839–1859, Mousumi Ghosh, Daniela Garcia-Castillo, Vladimir Aguirre, Roozbeh Golshani, Coleen M. Atkins, Helen M. Bramlett, W. Dalton Dietrich and Damien D. Pearse

    Version of Record online : 2 AUG 2012, DOI: 10.1002/glia.22401

  14. Phosphodiesterases and Cyclic Nucleotide Signaling In The CNS

    Cyclic-Nucleotide Phosphodiesterases In The Central Nervous System: From Biology to Drug Discovery

    Marco Conti, Wito Richter, Pages: 1–46, 2014

    Published Online : 7 MAR 2014, DOI: 10.1002/9781118836507.ch01

  15. Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement, and affect

    Journal of Comparative Neurology

    Volume 407, Issue 2, 3 May 1999, Pages: 287–301, James A. Cherry and Ronald L. Davis

    Version of Record online : 25 MAR 1999, DOI: 10.1002/(SICI)1096-9861(19990503)407:2<287::AID-CNE9>3.0.CO;2-R

  16. You have free access to this content
    Alteration of vascular reactivity in heart failure: role of phosphodiesterases 3 and 4

    British Journal of Pharmacology

    Volume 171, Issue 23, December 2014, Pages: 5361–5375, F Hubert, M Belacel-Ouari, B Manoury, K Zhai, V Domergue-Dupont, P Mateo, F Joubert, R Fischmeister and V Leblais

    Version of Record online : 24 NOV 2014, DOI: 10.1111/bph.12853

  17. You have free access to this content
    Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments

    British Journal of Pharmacology

    Volume 165, Issue 5, March 2012, Pages: 1288–1305, Thérèse Keravis and Claire Lugnier

    Version of Record online : 10 FEB 2012, DOI: 10.1111/j.1476-5381.2011.01729.x

  18. Genetic polymorphisms for the study of multifactorial stroke

    Human Mutation

    Volume 29, Issue 6, June 2008, Pages: 776–795, A. Bersano, E. Ballabio, N. Bresolin and L. Candelise

    Version of Record online : 17 APR 2008, DOI: 10.1002/humu.20666

  19. Pharmacological Manipulation of Cyclic Nucleotide Phosphodiesterase Signaling for The Treatment of Neurological and Psychiatric Disorders In The Brain

    Cyclic-Nucleotide Phosphodiesterases In The Central Nervous System: From Biology to Drug Discovery

    Frank S. Menniti, Niels Plath, Niels Svenstrup, Christopher J. Schmidt, Pages: 77–114, 2014

    Published Online : 7 MAR 2014, DOI: 10.1002/9781118836507.ch04

  20. Emerging Role for PDE4 in Neuropsychiatric Disorders: Translating Advances from Genetic Studies Into Relevant Therapeutic Strategies

    Cyclic-Nucleotide Phosphodiesterases In The Central Nervous System: From Biology to Drug Discovery

    Sandra P. Zoubovsky, Akira Sawa, Nicholas J. Brandon, Pages: 211–222, 2014

    Published Online : 7 MAR 2014, DOI: 10.1002/9781118836507.ch08